Merck & Co., Inc. $MRK Stock: Hengehold Capital Management LLC Reduces Position

Key Points

• Hengehold Capital Management cut its Merck position by 20.7% in the third quarter, selling 9,805 shares and retaining 37,648 shares valued at approximately $5.47 million. Institutional investors still own 76.07% of the company.
• Merck shares traded around $146, near their 52-week high, with the stock up significantly above its 200-day moving average. Analysts maintain a “Moderate Buy” consensus and an average price target of $151.92.
• Merck reported quarterly revenue of $16.61 billion, above expectations, and raised its outlook to $2.66–$2.76 in fiscal 2026 EPS guidance. The company also paid a quarterly dividend of $0.85, representing a 2.3% annualized yield.

Hengehold Capital Management LLC lowered its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 20.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,648 shares of the company's stock after selling 9,805 shares during the period. Hengehold Capital Management LLC's holdings in Merck & Co., Inc. were worth $5,471,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MRK. Dimensional Fund Advisors LP lifted its holdings in Merck & Co., Inc. by 23.8% in the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company's stock valued at $1,858,938,000 after acquiring an additional 2,969,856 shares during the period. Bank of America Corp DE grew its stake in shares of Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Corient Private Wealth LLC grew its stake in shares of Merck & Co., Inc. by 114.7% during the 4th quarter. Corient Private Wealth LLC now owns 5,210,548 shares of the company's stock valued at $548,462,000 after purchasing an additional 2,783,482 shares during the period. Employees Provident Fund Board bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $254,206,000. Finally, Diamant Asset Management Inc. increased its position in shares of Merck & Co., Inc. by 12,130.3% during the 1st quarter. Diamant Asset Management Inc. now owns 2,068,387 shares of the company's stock valued at $248,806,000 after purchasing an additional 2,051,475 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Performance

MRK traded up $0.82 during midday trading on Friday, reaching $146.01. The company had a trading volume of 11,231,621 shares, compared to its average volume of 10,199,042. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The business has a 50-day moving average of $145.60 and a two-hundred day moving average of $129.24. The company has a market cap of $360.22 billion, a P/E ratio of 116.81, a P/E/G ratio of 6.71 and a beta of 0.21. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the company earned $2.13 earnings per share. The business's revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is currently 272.00%.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Chirfi Guindo sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares of the company's stock, valued at approximately $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last 90 days. Insiders own 0.17% of the company's stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine. Positive clinical data could strengthen confidence in Merck’s oncology franchise and support longer-term growth. Merck reports promising skin cancer trial results
• Positive Sentiment: Merck is scheduled to present first-time pivotal Phase 3 oncology results at ESMO 2026, including melanoma and endometrial-cancer programs, alongside an oncology investor event. The disclosures may demonstrate progress in replacing or extending revenue from existing cancer therapies. Merck ESMO 2026 oncology pipeline preview
• Positive Sentiment: Merck’s continued uptrend has encouraged options traders to consider bullish strategies, indicating that some market participants expect further gains. Options activity, however, can amplify volatility and does not by itself change the company’s fundamentals. Merck bullish options strategy
• Neutral Sentiment: Merck’s investment narrative has shifted toward oncology and other growth opportunities as investors look beyond challenges affecting Gardasil, particularly in China. The strategy could improve diversification, but execution and pipeline commercialization remain key.
• Neutral Sentiment: Merck is being compared favorably with other pharmaceutical companies on dividend sustainability and cash generation, though the articles do not identify a major new dividend announcement. Merck versus Amgen dividend comparison
• Negative Sentiment: After rising more than 38% in 2026, Merck trades at a substantially higher forward earnings multiple than in late 2025. Analysts warn that the market may already be pricing in significant pipeline success, leaving less room for upside and greater sensitivity to disappointing trial data. Merck valuation and rally analysis

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MRK. Sanford C. Bernstein increased their price objective on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a "market perform" rating in a research note on Tuesday, August 4th. Guggenheim boosted their target price on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a "buy" rating in a research report on Tuesday, September 8th. Wolfe Research upped their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an "outperform" rating in a report on Tuesday, August 25th. Jefferies Financial Group upped their target price on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Finally, Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price target on the stock in a research report on Wednesday, August 12th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $151.92.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.